Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (NYSE American/TASE: LCTX) reported second quarter 2026 revenue of $1.1 million, down $1.7 million year over year, and total operating expenses of $10.0 million, down from $22.5 million mainly due to a prior-year VAC platform impairment. Loss from operations was $8.9 million, while other income of $10.5 million related primarily to non-cash warrant liability remeasurement contributed to net income of $1.5 million versus a $30.5 million loss a year ago. Cash, cash equivalents, and marketable securities totaled $50.8 million at June 30, 2026, which the company expects to fund operations into Q3 2028.
Lineage highlighted 3‑year Phase 1/2a OpRegen (RG6501) data with sustained BCVA gains and retinal structural changes, progress on its wholly owned corneal program COR1, ongoing enrollment in the OPC1 DOSED spinal cord injury study, advancement of the ReSonance (ANP1) hearing loss collaboration, scale-up under the ILT1 manufacturing initiative, and formation of a Scientific Advisory Board with Joachim Fruebis, PhD as founding member.
Lineage Cell Therapeutics (NYSE American/TASE: LCTX) will report its second quarter 2026 financial and operating results on August 6, 2026, after the U.S. market close, and will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT.
Investors can join by dialing (800) 715-9871 in the U.S. and Canada using Conference ID 2355043, or via a live webcast in the Investors section of the company’s website. A webcast replay will be available for 30 days, and a telephone replay at (800) 770-2030 through August 13, 2026. Lineage is a clinical-stage biotechnology company developing allogeneic “off the shelf” cell therapies via its AlloSCOPE platform, with programs including OpRegen, OPC1, ReSonance (ANP1), PNC1, RND1, ILT1, and COR1.
Lineage Cell Therapeutics (NYSE American, TASE: LCTX) provided an update on COR1, its allogeneic corneal endothelial cell (CEnC) transplant program for corneal endothelial disease, currently in preclinical development. COR1 uses a pluripotent cell-derived, “off the shelf” CEnC supply intended to address limitations of cadaver-derived donor cells such as restricted supply, variable quality, complex handling, and short shelf-life.
According to the company, COR1 is manufactured via the proprietary AlloSCOPE 5D platform, enabling bioreactor-based expansion and differentiation and a cryopreserved “thaw and inject” formulation for immediate use and long-term storage. Lineage reports that COR1 currently meets internal thresholds for potency, identity and scale, is being advanced into in-vivo animal testing with initial data expected this year, and that a two-tiered GMP banking system may be capable of generating millions of final product doses.
Lineage Cell Therapeutics (NYSE American:LCTX) announced that CEO Brian M. Culley will participate in a fireside chat at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit on July 16, 2026, at the InterContinental Boston hotel.
Investor meetings are available by invitation through B. Riley Securities.
Lineage Cell Therapeutics (NYSE American:LCTX) reported Q1 2026 results and a broad business update.
Revenue rose to $1.7M, with a net loss of $4.8M, and cash of $53.4M expected to fund operations into Q2 2028. Key updates included positive 3‑year RG6501 OpRegen Phase 1/2a data, continued Phase 2a GAlette enrollment with Roche/Genentech, treatment of a second chronic SCI patient in the OPC1 DOSED study, launch of COR1 for corneal endothelial disease, and the first milestone in the AlloSCOPE 5D/ILT1 manufacturing initiative. The company also advanced its ReSonance (ANP1) hearing loss program under a WDI collaboration, formed a Scientific Advisory Board led by Joachim Fruebis, PhD, and appointed Priyantha Herath, MD, PhD, as Senior Vice President & Head of Clinical.
Lineage Cell Therapeutics (NYSE American/TASE: LCTX) will report first quarter 2026 financial and operating results on May 12, 2026 after U.S. market close and will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT the same day to provide a business update.
Dial-in, conference ID, live webcast and replay details will be available via the company’s investors website; a telephone replay will be available through May 19, 2026.
Lineage (NYSE American: LCTX) reported 36-month Phase 1/2a data for RG6501 (OpRegen) in geographic atrophy (GA). Cohort 4 treated eyes (n=10) showed mean BCVA +6.2 ETDRS letters at 36 months; a subgroup with extensive bleb coverage (n=5) showed +9.0 letters. Quantitative OCT showed sustained RPE-C and ELM structural improvements versus fellow eyes through 36 months after a single subretinal administration. The GAlette surgical optimization Phase 2a study is enrolling to refine delivery methods and devices.
Lineage (NYSE American: LCTX) on April 13, 2026 announced formation of a Scientific Advisory Board (SAB) with Joachim Fruebis, Ph.D., as founding member, and appointed Priyantha Herath, M.D., Ph.D., as Senior Vice President and Head of Clinical Operations. The SAB will advise development of Lineage’s AlloSCOPE™ allogeneic cell transplant pipeline; additional members are expected later in 2026.
The appointments emphasize cross-therapeutic expertise in ophthalmology, neurology, and translational clinical development to support preclinical and clinical advancement of the company’s cell therapy programs.
Lineage (NYSE: LCTX) launched COR1, a new internally developed corneal endothelial cell (CEnC) therapy program in preclinical development for corneal endothelial disease, including Fuchs Endothelial Corneal Dystrophy and bullous keratopathy. Lineage reports manufacturing of off-the-shelf CEnCs that meet initial internal identity, morphological, and functional criteria using its AlloSCOPE platform.
The company cites donor shortages (one donor per 70 diseased eyes) and aims to leverage AlloSCOPE and a proprietary pluripotent cell line to scale production and potentially reduce costs via its AlloSCOPE “5D” process.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 and full‑year 2025 results and a business update highlighting clinical, manufacturing, and collaboration milestones. Key points include achieving the first milestone under the Roche/Genentech collaboration, positive 36‑month OpRegen data, a WDI research pact up to $12M, expanded AlloSCOPE manufacturing capability, and cash of $55.8M expected to support operations into Q2 2028.